Case report highlights thrombotic risks in ROS1-positive lung cancer patients undergoing crizotinib treatment, indicating the need for careful monitoring.
A 57-year-old woman with a ROS1-rearranged NSCLC patient demonstrated a Lazarus response to crizotinib but later developed recurrent pulmonary embolism (PE) with right ventricular (RV) failure. This incident highlights the potential crizotinib-related thrombotic risk and the need for appropriate monitoring of vascular complications, particularly in limited-option settings such as Thailand.
No takes yet. Share an insight, caveat, or question.
Patrathiranond et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: